Goldman Sachs Group Inc Allogene Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $613 Billion
- Q4 2024
A detailed history of Goldman Sachs Group Inc transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 2,106,577 shares of ALLO stock, worth $2.97 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,106,577
Previous 2,162,603
2.59%
Holding current value
$2.97 Million
Previous $6.06 Million
25.9%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding ALLO
# of Institutions
170Shares Held
132MCall Options Held
59.4KPut Options Held
113K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$26.4 Million1.25% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$23.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8MShares$11.3 Million0.0% of portfolio
-
State Street Corp Boston, MA7.01MShares$9.89 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA6.9MShares$9.72 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $203M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...